<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04394065</url>
  </required_header>
  <id_info>
    <org_study_id>2020-5-13 high-sensitivity PET</org_study_id>
    <nct_id>NCT04394065</nct_id>
  </id_info>
  <brief_title>Ultrasensitive Positron Emission Tomography in NPC Patients</brief_title>
  <official_title>Subsecond Total-body Imaging Using Ultrasensitive Positron Emission Tomography in Nasopharyngeal Carcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ultrasensitive PET in newly diagnosed nasopharyngeal carcinoma may benifit the patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner
      (uEXPLORER), has been constructed to offer a transformative platform for human radiotracer
      imaging in clinical research and healthcare. The objective of this study is to determine its
      specific effect in newly diagnosed nasopharyngeal carcinoma
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 20, 2020</start_date>
  <completion_date type="Anticipated">December 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>The results of ultrasensitive positron emission tomography</measure>
    <time_frame>6 months</time_frame>
    <description>The results of ultrasensitive positron emission tomography in newly diagnosed NPC, including images; metabolic status of FDG; specificity and sensitivity in diagnosing NPC.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Ultrasensitive PET CT</arm_group_label>
    <description>Newly diagnosed NPC patients will undergo ultrasensitive PET CT before treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ultrasensitive positron emission tomography</intervention_name>
    <description>A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER)</description>
    <arm_group_label>Ultrasensitive PET CT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        newly diagnosed NPC
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be informed of the investigational nature of this study and given
             written informed consent.

          -  Aged between 18-65, male/female.

          -  Histologically confirmed non-keratinizing nasopharyngeal carcinoma (including
             differentiated type and undifferentiated type, WHO II and III)..

          -  Fertile women should practice contraception during the study period.

          -  HGB ≥90g/L ,WBC ≥4*109/L , PLT ≥100*109/L,

          -  With normal liver function test (ALT and AST ≤2.5*ULN, TBil ≤2.0*ULN)

          -  With normal renal function test (serum creatinine ≤1.5*ULN)

        Exclusion Criteria:

          -  Women in pregnancy or lactation

          -  Prior malignancy except adequately treated basal cell, squamous cell skin cancer, or
             cervical cancer in situ.

          -  Any severe intercurrent disease, which may bring unacceptable risk or affect the
             compliance of the trial, for example, unstable cardiac disease requiring treatment,
             renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose
             &gt;1.5×ULN), and emotional disturbance.

          -  Already involved in other clinical trial.

          -  Mental disorder, civil disability, limited capacity for civil conduct.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Haiqiang Mai, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haiqiang Mai, Dr</last_name>
    <phone>86-20-8734-3643</phone>
    <email>maihq@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zhang X, Cherry SR, Xie Z, Shi H, Badawi RD, Qi J. Subsecond total-body imaging using ultrasensitive positron emission tomography. Proc Natl Acad Sci U S A. 2020 Feb 4;117(5):2265-2267. doi: 10.1073/pnas.1917379117. Epub 2020 Jan 21.</citation>
    <PMID>31964808</PMID>
  </reference>
  <results_reference>
    <citation>Lv Y, Lv X, Liu W, Judenhofer MS, Zwingenberger A, Wisner E, Berg E, McKenney S, Leung E, Spencer BA, Cherry SR, Badawi RD. Mini EXPLORER II: a prototype high-sensitivity PET/CT scanner for companion animal whole body and human brain scanning. Phys Med Biol. 2019 Mar 21;64(7):075004. doi: 10.1088/1361-6560/aafc6c.</citation>
    <PMID>30620929</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hai-Qiang Mai,MD,PhD</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>ultrasensitive PET CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

